DVA vs MNKD
DVA: Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant support globally. MNKD: MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic and orphan lung diseases.
Side-by-side fundamentals
| Metric | DVA | MNKD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $232.08 | $3.84 | |
| Market cap as of 2026-07-23 | $15.0B | $1.2B | |
| P/E as of 2026-07-23 | 19.22 | 212.36 | DVA lower |
| PEG as of 2026-07-23 | 7.29 | n/a | |
| Net margin as of 2026-07-23 | +5.7% | -6.4% | DVA higher |
| Gross margin as of 2026-07-23 | +32.5% | +78.4% | MNKD higher |
| Operating margin as of 2026-07-23 | +15.0% | +4.1% | DVA higher |
| ROE as of 2026-07-23 | +181.2% | -297.7% | DVA higher |
| ROA as of 2026-07-23 | +4.5% | -3.8% | DVA higher |
| Debt / equity as of 2026-07-23 | 77.99 | 9.95 | MNKD lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.7% | +21.2% | MNKD higher |
| Revenue CAGR (3y) SEC XBRL | +5.5% | +51.8% | MNKD higher |
| Beta as of 2026-07-23 | 0.88 | 1.12 | |
| 1-year return as of 2026-07-22 close | +58.9% | -2.3% | DVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.